A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer

​ Conditions: CRC

Interventions: Drug; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276

Sponsors: Genfleet Therapeutics (Shanghai) Inc.

Not yet recruiting Conditions: CRC
Interventions: Drug; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276
Sponsors: Genfleet Therapeutics (Shanghai) Inc.
Not yet recruiting